LC
Lisa A. Carey
Highly rated in
10
conditions

Dr. Lisa A. Carey

UNC Hospitals Adult Oncology Clinics
Chapel Hill, NC
Highly rated in
10
conditions
Specialties:Oncology | Hematology Oncology
Experience:33 Years
Clinical Trials:Currently Recruiting for 13 Trials
Accepts:New PatientsMedicare
Highly rated in
10
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Lisa A. Carey's experience treating your condition:
About Dr. Lisa A. Carey

Lisa Carey is an Oncologist and a Hematologist Oncology expert in Chapel Hill, North Carolina. Carey has been practicing medicine for over 33 years and is highly rated in 10 conditions, according to our data. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, and HER2 Negative Breast Cancer. She is licensed to treat patients in North Carolina. Carey is currently accepting new patients.

Her clinical research consists of co-authoring 265 peer reviewed articles and participating in 33 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Lisa A. Carey it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Dr. Lisa A. Carey accepts the following insurance:

  •  Blue Cross Blue Shield
  •  UnitedHealthcare
Call to see if your plan is accepted.
Locations
101 Manning Dr, 2nd Floor, Chapel Hill, NC 27514
Background & Education
Graduate Institution
Johns Hopkins University School Of Medicine, 1990
Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in NC
Hospital Affiliations
The Outer Banks Hospital
UNC Medical Center
Languages Spoken
English
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

31 Clinical Trials
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Recruiting
Publish Date: December 13, 2022
Intervention Type: Drug
Study Drugs: tucatinibT-DM1
Study Phase: Phase 3
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
Enrollment Status: Recruiting
Publish Date: December 12, 2022
Intervention Type: Drug
Study Drugs: LY3484356AbemaciclibEverolimusAlpelisibTrastuzumabAromatase Inhibitor
Study Phase: Phase 1
AURORA US: Prospective Biospecimen Repository in Metastatic Breast Cancer
Enrollment Status: Recruiting
Publish Date: December 12, 2022
Intervention Type: Procedure, Other
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Enrollment Status: Recruiting
Publish Date: December 05, 2022
Intervention Type: Drug
Study Drugs: ImlunestrantExemestaneFulvestrantAbemaciclib
Study Phase: Phase 3
HARMONY: Harnessing the Analysis of RNA Expression and Molecular Subtype to Optimize Novel TherapY for Metastatic Breast Cancer
Enrollment Status: Recruiting
Publish Date: November 29, 2022
Intervention Type: Device
Study Phase: Not Applicable
MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast Cancer
Enrollment Status: Recruiting
Publish Date: November 25, 2022
Intervention Type: Drug
Study Drugs: PaclitaxelPertuzumabMargetuximabTrastuzumab
Study Phase: Phase 2
Saci-IO HR+: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in Hormone Receptor-positive (HR+) / HER2- Metastatic Breast Cancer (MBC)
Enrollment Status: Recruiting
Publish Date: November 16, 2022
Intervention Type: Drug
Study Drugs: PembrolizumabSacituzumab Govitecan
Study Phase: Phase 2
Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer (TNBC)
Enrollment Status: Recruiting
Publish Date: November 16, 2022
Intervention Type: Drug
Study Drugs: Sacituzumab GovitecanPembrolizumab
Study Phase: Phase 2
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer
Enrollment Status: Recruiting
Publish Date: October 28, 2022
Intervention Type: Drug
Study Drugs: tucatinibtrastuzumab deruxtecan
Study Phase: Phase 2
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Recruiting
Publish Date: September 19, 2022
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: DocetaxelNab-PaclitaxelPaclitaxelPertuzumabTrastuzumabTrastuzumab Emtansine
Study Phase: Phase 2
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
Enrollment Status: Recruiting
Publish Date: June 09, 2022
Intervention Type: Other, Procedure
A Phase III, Multicenter, Open-label Study of Ribociclib vs. Palbociclib in Patients With Advanced Hormone Receptor-positive/HER2-negative/HER2-Enriched Breast Cancer - HARMONIA Trial
Enrollment Status: Recruiting
Publish Date: April 04, 2022
Intervention Type: Drug
Study Drugs: RibociclibLetrozoleFulvestrantPalbociclibPaclitaxel
Study Phase: Phase 3
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
Enrollment Status: Recruiting
Publish Date: February 17, 2022
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab EmtansineTucatinib
Study Phase: Phase 3
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Enrollment Status: Active, not recruiting
Publish Date: December 12, 2022
Intervention Type: Other, Drug
Study Drugs: CisplatinVeliparib
Study Phase: Phase 2
A Phase II Open-label, Randomized, Three-arm, Multicenter Study of LAG525 Given in Combination With Spartalizumab (PDR001), or With Spartalizumab and Carboplatin, or With Carboplatin, as First or Second Line Therapy in Patients With Advanced Triple-negative Breast Cancer
Enrollment Status: Completed
Publish Date: December 06, 2022
Intervention Type: Drug
Study Drugs: LAG525spartalizumabcarboplatin
Study Phase: Phase 2
Randomized Phase III Trial of Paclitaxel +Trastuzumab + Lapatinib Versus Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer
Enrollment Status: Active, not recruiting
Publish Date: November 17, 2022
Intervention Type: Biological, Other, Drug
Study Drugs: Lapatinib DitosylatePaclitaxelTrastuzumab
Study Phase: Phase 3
A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer
Enrollment Status: Active, not recruiting
Publish Date: October 25, 2022
Intervention Type: Drug, Procedure
Study Drugs: TrastuzumabPertuzumab
Study Phase: Phase 2
Quantification and Characterization of Circulating Tumor Cells in Solid Tumors
Enrollment Status: Completed
Publish Date: September 28, 2022
Intervention Type: Other
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: September 13, 2022
Intervention Type: Drug
Study Drugs: tucatinibcapecitabinetrastuzumab
Study Phase: Phase 2
A Phase Ib/II Trial of Taselisib (GDC-0032), a PI3K Inhibitor, in Combination With Enzalutamide in Patients With Androgen Receptor Positive Triple Negative Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: August 22, 2022
Intervention Type: Drug, Other
Study Drugs: EnzalutamideTaselisib
Study Phase: Phase 1/Phase 2
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Enrollment Status: Active, not recruiting
Publish Date: August 03, 2022
Intervention Type: Drug
Study Drugs: FulvestrantAnastrozole
Study Phase: Phase 3
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
Enrollment Status: Completed
Publish Date: June 15, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Non-randomized, Non-comparative, Open-label, Window Trial of Entinostat Given With or Without Exemestane in Patients With Newly Diagnosed, Stage I-IIIC, Hormone Receptor - Positive (HR+) or Triple Negative Breast Cancer (TNBC)
Enrollment Status: Terminated
Publish Date: March 25, 2021
Intervention Type: Drug
Study Phase: Early Phase 1
Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib
Enrollment Status: Completed
Publish Date: September 04, 2020
Intervention Type: Drug
Study Phase: Early Phase 1
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212
Enrollment Status: Completed
Publish Date: September 02, 2020
Intervention Type: Drug
Study Phase: Early Phase 1
LCCC 1410: Impact of Physical Activity on Biomarker of Aging and Body Composition Among Breast Cancer Survivors Age 65 and Older
Enrollment Status: Completed
Publish Date: April 30, 2020
Intervention Type: Behavioral
Study Phase: Not Applicable
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Impact of a Physical Activity Program on Biomarkers of Aging During Adjuvant or Neoadjuvant Chemotherapy for Breast Cancer
Enrollment Status: Completed
Publish Date: June 06, 2018
Intervention Type: Behavioral
A Randomized, Wait-list Controlled Clinical Trial: the Effect of a Physical Activity Program on Fatigue After Potentially Curative Chemotherapy Among Cancer Survivors Age 65 or Older -- PACT (Physical Activity After Chemotherapy)
Enrollment Status: Completed
Publish Date: September 12, 2017
Intervention Type: Behavioral
Study Phase: Not Applicable
Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population
Enrollment Status: Completed
Publish Date: August 01, 2017
Intervention Type: Other, Drug, Procedure, Genetic
Study Phase: Phase 2
Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: June 28, 2017
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 18 Less Clinical Trials -
265 Total Publications
Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 04, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
TS
Dr. Thomas E. Stinchcombe
Oncology | Hematology Oncology
Highly rated in
13
conditions
Oncology
Hematology Oncology

Duke Health

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
 9.4 mi

Thomas Stinchcombe is an Oncologist and a Hematologist Oncology expert in Durham, North Carolina. Stinchcombe has been practicing medicine for over 28 years and is highly rated in 13 conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NCSLC), Lung Cancer, Squamous Cell Lung Carcinoma, EGFR Positive Lung Cancer, and Gamma Knife Radiosurgery. He is licensed to treat patients in North Carolina. Stinchcombe is currently accepting new patients.

MM
Dr. Matthew I. Milowsky
Hematology Oncology | Oncology
Highly rated in
16
conditions
Hematology Oncology
Oncology

UNC Health

UNC Hospitals Adult Oncology Clinics

101 Manning Dr, 
Chapel Hill, NC 

Matthew Milowsky is a Hematologist Oncology specialist and an Oncologist in Chapel Hill, North Carolina. Milowsky has been practicing medicine for over 27 years and is highly rated in 16 conditions, according to our data. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Renal Cell Carcinoma (RCC), Tissue Biopsy, and Prostatectomy. He is licensed to treat patients in New York. Milowsky is currently accepting new patients.

CA
Carey K. Anders
Dr. Carey K. Anders
Oncology | Hematology Oncology
Highly rated in
9
conditions
Oncology
Hematology Oncology

Duke Health

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
 9.4 mi

Carey Anders is an Oncologist and a Hematologist Oncology expert in Durham, North Carolina. Anders has been practicing medicine for over 21 years and is highly rated in 9 conditions, according to our data. Her top areas of expertise are Triple-Negative Breast Cancer, Metastatic Brain Tumor, Breast Cancer, Brain Tumor, and Gamma Knife Radiosurgery. She is licensed to treat patients in North Carolina. Anders is currently accepting new patients.